Genentech, Inc.

F. Hoffmann-La Roche Ag

F. Hoffmann-La Roche Sa

Malcolm Huestis

Michael Siu

Snahel Patel

Anthony A Estrada

Terry Kellar

Joseph P Lyssikatos

Jun Liang

Alan G Olivero

Daniel Shore

Andrew Madin

Bryan K Chan

Eileen Mary Seward

Lewis J Gazzard

Kevin X Chen

BinQing Wei

Timothy Heffron

Graham Elgin Jones

Sushant Malhotra

Emanuela Gancia

Paul Gibbons

Craig Stivala

Weiru Wang

Michael Lainchbury

Kin Chiu Fong

Rohan V Mendonca

Naomi S Rajapaksa

Aihe Zhou

Yonghan Hu

Aijun Lu

Blake Daniels

Baihua Hu

John Tellis

Matthew W Cartwright

David Favor

Andrew Good

Wen Liu

Liting Dong

Changyou Ma

Bing-Yan Zhu

Xiaojing Wang

Frederick Cohen

Georgette M Castanedo

Binqing Wei

Joy Drobnick

Wen K Liu

Cuong Q Ly

Jason R Zbieg

Robin Larouche-Gauthier

Guibai Liang

Xianrui Zhao

Lisa Marie Barton

Michael John Lambrecht

Araz Jakalian

Fabio Broccatelli

Man Un Ung

Arun Yadav

Alan Olivero

Naomi Rajapaksa

Kevin Chen

A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.

Lactams as CBL-B inhibitors selective over C-CBL

The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R, R, R, X, X, A and Cy variable in Formula I-I all have the meaning as defined herein. 

Biheteroaryl compounds and uses thereof

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R, R, R, X, X, A and Cy variable in Formula all have the meaning as defined herein.

The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R-Rhave any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Tricyclic DLK inhibitors and uses thereof

The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof.  In compounds of Formula I, the groups R, R, R, R, R, R, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Substituted dipyridylamines and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Malcolm Huestis